Therapeutic agent for acute pain

Hydantoin compounds, particularly fosphenytoin, provide effective analgesia for acute pain by reducing opioid requirements and minimizing side effects, addressing the limitations of current opioid therapies.

JP2024165960APending Publication Date: 2024-11-28KYOTO PREFECTURAL PUBLIC UNIV CORP +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023082581
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-18
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current treatments for acute pain, particularly post-operative acute pain, are limited by the side effects of opioids such as respiratory depression, nausea, constipation, tolerance, and addiction, and there is a need for alternative analgesics that can reduce opioid use during the perioperative period.

Method used

A therapeutic agent using hydantoin compounds like phenytoin, fosphenytoin, mephenytoin, nirvanol, or amino(diphenylhydantoin)valeric acid, either alone or in combination with opioids, is administered to provide analgesia, with a preferred combination of fosphenytoin and morphine in specific weight ratios.

Benefits of technology

The hydantoin compounds effectively reduce acute pain and can significantly decrease the required dosage of opioids, offering a broader range of applicability and reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024165960000013
    Figure 2024165960000013
  • Figure 2024165960000014
    Figure 2024165960000014
  • Figure 2024165960000015
    Figure 2024165960000015
Patent Text Reader

Abstract

To provide a therapeutic agent for acute pain, such as postoperative pain.SOLUTION: The present invention provides a therapeutic agent for acute pain in the form of an injection, an oral formulation, or a transdermal preparation, containing a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin) valeric acid, and ethotoin as an active ingredient. Preferably, it is combined with the administration of opioids such as morphine.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel use of a compound used as a therapeutic agent for epilepsy. In particular, the present invention relates to a therapeutic agent for acute pain using a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin)valeric acid, and ethotoin as an active ingredient. [Background technology]

[0002] Acute pain, used synonymously with acute pain, usually occurs as a response to tissue injury and is generated by activation of peripheral pain receptors and corresponding sensory nerve fibers (nociceptors) composed of Aδ and C fibers (MSD Manual).

[0003] Nociceptive pain can be somatic or visceral. Somatic pain receptors are located in the skin, subcutaneous tissue, fascia, other connective tissues, periosteum, endosteum, and joint capsules. Stimulation of these receptors usually produces a localized sharp or dull pain, although a burning sensation is not uncommon if the skin or subcutaneous tissue is injured. Visceral pain receptors are located in most visceral organs and in the connective tissues surrounding them. Visceral pain due to obstruction of a hollow organ is poorly localized, cramp-like, deep pain that may be referred to the skin at a distant site. Visceral pain due to injury to the capsule of a viscera or other deep connective tissues may be more locally localized and sharp.

[0004] Currently, for acute pain, general analgesics (NSAIDs, selective COX-2 inhibitors, acetaminophen, etc.) are mainly used if the pain is mild, while opioids are used for severe pain.

[0005] In particular, management of acute postoperative pain after surgery is important for improving prognosis, and methods to reduce pain and side effects have been attempted by combining drugs with different mechanisms of action and nerve blocks. In current perioperative management, opioids (such as morphine) are used for intraoperative and postoperative analgesic management, and necessary opioids are continuously administered even after awakening from anesthesia to prevent severe pain after surgery. However, opioids have the problem of causing various side effects, such as respiratory depression, nausea, constipation, and the risk of tolerance, dependence, and addiction.

[0006] Pregabalin, carbamazepine, lidocaine, and other drugs may also be administered to treat acute pain following thoracic surgery.

[0007] In recent years, a technique has been developed in which hydantoin compounds such as phenytoin and fosphenytoin are used as therapeutic agents for acute herpes zoster pain (Patent Document 1).

[0008] However, Patent Document 1 does not specifically disclose application to acute pain, particularly postoperative acute pain. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] International Publication No. 2020 / 054872 Summary of the Invention [Problem to be solved by the invention]

[0010] An object of the present invention is to provide a new therapeutic agent for acute pain, particularly postoperative acute pain.

[0011] A further object of the present invention is to provide a method for treating acute pain, particularly acute post-operative pain.

[0012] Another object of the present invention is to provide an analgesic drug that can reduce the amount of opioid used during the perioperative period. [Means for solving the problem]

[0013] That is, the present invention provides the following items [1] to

[19] . [Item 1] A therapeutic agent for acute pain, comprising as an active ingredient a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin)valeric acid, and ethotoin.

[0014] [Item 2] The therapeutic agent according to Item 1, wherein the active ingredient is phenytoin or fosphenytoin.

[0015] [Item 3] The therapeutic agent according to Item 1, wherein the active ingredient is fosphenytoin.

[0016] [Item 4] The therapeutic agent according to Item 1, wherein the acute pain is postoperative pain.

[0017] [Item 5] The therapeutic agent according to Item 1, which is used in combination with administration of an opioid.

[0018] [Item 6] The therapeutic agent according to Item 5, wherein the opioid is morphine.

[0019] [Item 7] A pharmaceutical composition for treating acute pain, comprising a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin)valeric acid, and ethotoin, and a pharma- ceutically acceptable carrier.

[0020] [Item 8] The pharmaceutical composition according to Item 7, which is an injection, an oral preparation, or a transdermal preparation.

[0021] [Item 9] The pharmaceutical composition according to Item 7, which is an injection.

[0022] [Item 10] The pharmaceutical composition according to Item 7, wherein the active ingredient is phenytoin or fosphenytoin.

[0023] [Item 11] The pharmaceutical composition according to Item 7, wherein the active ingredient is fosphenytoin.

[0024] [Item 12] The pharmaceutical composition according to Item 7, wherein the acute pain is postoperative pain.

[0025] [Item 13] The pharmaceutical composition according to Item 7, which is used in combination with administration of an opioid.

[0026] [Item 14] The pharmaceutical composition according to Item 13, wherein the opioid is morphine.

[0027] [Item 15] The pharmaceutical composition according to Item 7, which is administered simultaneously with administration of an opioid.

[0028] [Item 16] The pharmaceutical composition according to Item 15, wherein the opioid is morphine.

[0029] [Item 17] The pharmaceutical composition according to Item 14 or 16, wherein the hydantoin compound is fosphenytoin and the opioid is morphine.

[0030] [Item 18] The pharmaceutical composition according to Item 14 or 16, wherein the weight ratio of the hydantoin compound to morphine is within the range of 1000:1 to 1:1000.

[0031] [Item 19] The pharmaceutical composition according to Item 18, wherein the weight ratio of fosphenytoin to morphine is within the range of 100:1 to 100:20.

[0032] Furthermore, the present invention provides the following: [Item 20] A method for treating acute pain, comprising administering to a patient in need of treatment a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin)valeric acid, and ethotoin.

[0033] [Item 21] A method for treating acute pain, comprising administering to a patient in need of treatment a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin)valeric acid, and ethotoin, and an opioid.

[0034] [Item 22] A method for treating acute pain, comprising simultaneously administering to a patient in need of treatment a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin)valeric acid, and ethotoin, and an opioid.

[0035] [Item 23] A method for treating acute pain, comprising administering fosphenytoin and morphine to a patient in need of treatment.

[0036] [Item 24] A method for treating acute pain, comprising administering fosphenytoin and morphine simultaneously to a patient in need of treatment. Effect of the Invention

[0037] According to the present invention, it is possible to provide a therapeutic drug for acute pain, particularly acute postoperative pain, which is applicable to a wide range of patients.

[0038] Furthermore, by using a hydantoin compound in combination with an opioid, it becomes possible to reduce the amount of opioid used during the perioperative period. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] The present invention will be described in detail below.

[0040] In the present invention, acute pain is used synonymously with acute pain, which usually occurs as a response to tissue damage and is generated by activation of peripheral pain receptors and corresponding sensory nerve fibers (nociceptors) composed of Aδ and C fibers (MSD Manual).

[0041] In the present invention, acute postoperative pain refers to pain caused by damage to nerve tissue or an inflammatory reaction at the site of injury after surgery, and is a type of acute pain.

[0042] In the present invention, the subject (patient) is a warm-blooded animal, and may be a human or non-human mammal. In one embodiment, the subject is a human.

[0043] Active ingredient The active ingredient used in the therapeutic agent of the present invention is a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin)valeric acid and ethotoin. Phenytoin is listed in the Japanese Pharmacopoeia, and is sold, for example, by Sumitomo Pharma Co., Ltd. under the trade name of Aleviatin or by Daiichi Sankyo Co., Ltd. under the trade name of Hydanthol, and fosphenytoin is sold by Nobelpharma Co., Ltd. under the trade name of Fostoin. Fosphenytoin is a prodrug of phenytoin. Ethotoin is sold by Sumitomo Pharma Co., Ltd. under the trade name of Axenon. On the other hand, mephenytoin, nirvanol, and amino(diphenylhydantoin)valeric acid are not currently commercially available, but are compounds that have long been known as therapeutic agents for epilepsy. Among them, phenytoin and fosphenytoin are preferred, and fosphenytoin is particularly recommended.

[0044] In particular, fosphenytoin is hydrolyzed by alkaline phosphatase in the living body to the active metabolite phenytoin, which acts as phenytoin, and has reduced side effects associated with phenytoin, and is therefore preferably used.

[0045] These active ingredients can be used alone or in combination.

[0046] Optical isomers of the active ingredient When the hydantoin compounds that are the active ingredients of the present invention contain an asymmetric center, such as ethotoin, they may exist as racemates and racemic mixtures, single enantiomers, and the present invention is intended to include all such isomers of the compounds, either as individual species or as mixtures thereof.

[0047] Salt of active ingredient The hydantoin compound, which is an active ingredient of the present invention, can be used in the form of a salt. For example, fosphenytoin has a phosphate group, and amino(diphenylhydantoin)valeric acid has an amino group and a carboxyl group, and the pharma- ceutical acceptable salts thereof can also be used.

[0048] In the present invention, the term "pharmaceutical acceptable salt" refers to a salt prepared from a pharmaceutical acceptable non-toxic base or acid. When the hydantoin compound of the present invention is acidic, its corresponding salt can be prepared from a pharmaceutical acceptable non-toxic base, including inorganic bases and organic bases. For example, such salts include aluminum, ammonium, calcium, copper (II and I), ferric, ferrous, lithium, magnesium, manganese (II and I), potassium, sodium, zinc, etc. Among them, ammonium, calcium, magnesium, potassium, and sodium salts are preferred. In particular, in the case of fosphenytoin, its sodium salt and potassium salt are preferred, and in particular, sodium salt is recommended.

[0049] On the other hand, when the hydantoin compound of the present invention is basic, its corresponding salt can be prepared from pharma- ceutically acceptable non-toxic inorganic and organic acids, such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucoic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, etc.

[0050] In particular, when the molecule has both an acidic group and a basic group, such as amino(diphenylhydantoin)valeric acid, it can exist in the form of a zwitterion.

[0051] It will of course be understood that references herein to the hydantoin compounds are meant to also include the pharma- ceutically acceptable salts.

[0052] Suitable dosage levels of the active ingredients used in the present invention are usually about 0.01-500 mg / kg of patient body weight / day and may be administered in single or multiple doses. Suitable dosage levels may be about 0.01-250 mg / kg / day, about 0.05-100 mg / kg / day, or about 0.1-50 mg / kg / day. Within this range, dosages may be 0.05-0.5, 0.5-5, or 5-50 mg / kg / day. The active ingredients may be administered on a dosing regime of 1-4 times per day, or may be administered once or twice per day.

[0053] However, it will be understood by those skilled in the art that the specific dose level and frequency of dosing for any particular patient will vary and depend upon a variety of factors, including the activity of the specific active ingredient employed, the metabolic stability and length of action of that active ingredient, age, body weight, general health, sex, diet, mode and frequency of administration, rate of excretion, drug combination, the severity of the particular condition, and the host being treated.

[0054] The active ingredients of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implantation), inhalation spray, nasal, vaginal, rectal, sublingual, buccal or topical routes of administration and, alone or together, may be formulated into suitable dosage unit formulations containing conventional non-toxic pharma- ceutically acceptable carriers appropriate for each route of administration.

[0055] Pharmaceutical Compositions The active ingredient of the therapeutic agent of the present invention is combined with pharmaceutically acceptable carrier and administered to patient as pharmaceutical composition.The pharmaceutical composition includes the composition suitable for oral, rectal, topical and parenteral (for example, subcutaneous, intramuscular and intravenous) administration, but the most suitable route in a given case depends on the specific host and the nature and severity of the disease condition that the active ingredient is administered to.

[0056] In general, pharmaceutical compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers, or both, and then, if necessary, shaping the product into the desired formulation. The active ingredient in the pharmaceutical composition is present in an amount sufficient to produce an effect on the process or condition of the disease.

[0057] The pharmaceutical composition containing the active ingredient is formulated into a form suitable for oral use, such as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, solutions, hard or soft capsules, or syrups or elixirs. Compositions for oral use can be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions can contain one or more agents selected from the group consisting of sweeteners, flavoring agents, coloring agents, and preservatives. Tablets contain the active ingredient mixed with non-toxic pharma- ceutically acceptable excipients suitable for the manufacture of tablets. These excipients may be inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as corn starch or alginic acid; binding agents, such as starch, gelatin, or gum arabic; and lubricants, such as magnesium stearate, stearic acid, or talc. The tablets may be uncoated or may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over a longer period. For example, a time-delay material such as glyceryl monostearate or glyceryl distearate may be used. They may also be coated by conventional methods to form osmotically therapeutic tablets for controlled release. Oral tablets may also be formulated for immediate release, such as fast-dissolving tablets or wafers, rapid-dissolving tablets or films.

[0058] Formulations for oral use may also be presented as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin, or olive oil.

[0059] Aqueous suspensions contain the active ingredient mixed with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum arabic; dispersing or wetting agents may be naturally occurring phospholipids, such as lecithin, or condensation products of alkylene oxides with fatty acids, such as polyoxyethylene stearate, or condensation products of ethylene oxide with long-chain aliphatic alcohols, such as heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitols, such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, such as polyethylene sorbitan monooleate. Aqueous suspensions may also contain preservatives, such as ethyl or n-propyl, p-hydroxybenzoates, coloring agents, flavoring agents, and sweetening agents, such as sucrose or saccharin.

[0060] Oily suspensions can be formulated by suspending the active ingredient in vegetable oil, such as peanut oil, olive oil, sesame oil or coconut oil, or in mineral oil, such as liquid paraffin.Oily suspensions can contain thickening agents, such as beeswax, hard paraffin or cetyl alcohol.Sweeteners and flavorings, such as those mentioned above, can be added to obtain a palatable oral preparation.These compositions can be preserved by adding an antioxidant, such as ascorbic acid.

[0061] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, such as sweeteners, flavorings and coloring agents, may also be present.

[0062] The pharmaceutical compositions of the invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as liquid paraffin, or a mixture thereof. Suitable emulsifiers are naturally occurring gums, such as gum arabic or gum tragacanth, naturally occurring phospholipids, such as soybean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of said partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. These emulsions can also contain sweeteners and flavoring agents.

[0063] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose, and such preparations may also contain a demulcent, a preservative and flavouring and colouring agents.

[0064] The pharmaceutical composition of the present invention may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated by known techniques using the above-mentioned dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Acceptable vehicles or solvents include water, Ringer's solution and isotonic saline solution. In addition, the vehicle or solvent for the oily suspension may include any non-irritating non-volatile oil, such as synthetic monomeric or diglycerides.

[0065] The pharmaceutical composition of the present invention can also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at rectal temperature, and therefore melts in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycol.

[0066] For topical administration, such as transdermal absorption, creams, ointments, jellies, solutions or suspensions, etc., containing the active ingredients of the present invention may be used. Similarly, transdermal patches may also be used for topical administration.

[0067] Among the above forms, the pharmaceutical composition of the present invention is preferably in the form of an injection, an oral preparation, or a transdermal preparation.

[0068] Furthermore, since the therapeutic agent of the present invention is used for the treatment of acute pain, the pharmaceutical composition is preferably a preparation for injection, particularly for intravenous injection, so that the blood concentration rises immediately after administration and the effect can be exhibited.

[0069] Use in combination with other drugs (combination therapy) The pharmaceutical composition of the present invention can be used in combination with other drugs to enhance its effect. Such other drugs can be administered simultaneously or sequentially with the pharmaceutical composition of the present invention, by a route and in an amount generally used therefor. The pharmaceutical composition of the present invention can generally be administered to a patient who is already taking one or more other drugs for the condition. The pharmaceutical composition of the present invention can also be administered to a patient who is already being treated with one or more acute pain medications, if the patient's pain does not respond adequately to the treatment.

[0070] Combination therapy also includes therapy in which the pharmaceutical composition of the present invention and one or more other drugs are administered on different overlapping schedules.It is also contemplated that when used in combination with one or more other drugs, the pharmaceutical composition of the present invention and the other drug can be used in lower doses than when each is used alone.Therefore, the pharmaceutical composition of the present invention can also include a pharmaceutical composition that contains one or more other drugs in addition to the pharmaceutical composition of the present invention.

[0071] Such other drugs include opioids; calcium channel antagonists; NMDA receptor agonists; NMDA receptor antagonists; COX-2 selective inhibitors; NSAIDs (nonsteroidal anti-inflammatory drugs); and analgesics.

[0072] In particular, opioids such as codeine phosphate, morphine, oxycodone, fentanyl, remifentanil, meperidine, tramadol, buprenorphine, pentazocine, etc. are preferred, and among these, morphine, fentanyl, etc. are preferred.

[0073] The present invention further provides a method of treating acute pain, which comprises administering to a patient in need of such treatment a particular amount of a pharmaceutical composition of the present invention and a particular amount of another agent effective to treat the condition, which together provide effective relief.

[0074] The weight ratio of the hydantoin compound and other drugs in the pharmaceutical composition of the present invention can vary and depends on the effective dose of each component. In general, each effective dose is used. Thus, for example, when the hydantoin compound of the present invention is combined with an opioid, the weight ratio of the hydantoin compound of the present invention to the opioid is within the range of about 1000:1 to about 1:1000, preferably within the range of about 200:1 to about 1:200, when the opioid is morphine. In particular, the weight ratio of fosphenytoin to morphine is recommended to be within the range of 100:1 to 100:20.

[0075] Combinations of a hydantoin compound of this invention with other drugs will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used. EXAMPLES

[0076] The present invention will be described below with reference to specific embodiments, but it will be understood that the present invention is not limited to these embodiments, and that various changes and modifications therein can be made by those skilled in the art without departing from the scope or spirit of the present invention as defined in the appended claims.

[0077] Experimental content (1) Analgesic effect against acute pain The responses to mechanical and thermal stimuli in the incision model will be evaluated by behavioral analysis in the fosphenytoin group (3 mg / kg, 10 mg / kg, 30 mg / kg, 6 mice each), morphine group (0.3 mg / kg, 1 mg / kg, 3 mg / kg, 6 mice each), and vehicle group (6 mice). (2) Morphine analgesic enhancement effect on acute pain Morphine analgesic enhancement effect on acute pain In an incision model, the responses to mechanical and thermal stimuli in the fosphenytoin (non-analgesic dose) + morphine groups (0.3mg / kg, 1mg / kg, 3mg / kg, 6 animals each) and the morphine only groups (0.3mg / kg, 1mg / kg, 3mg / kg, 6 animals each) are analyzed by behavioral analysis, and the enhancement effect of the morphine analgesic effect is compared with the morphine only group. (3) Inhibitory effect of pERK1 / 2 expression during acute pain The suppression of phosphorylated extracellular signal-regulated kinase 1 / 2 (pERK1 / 2) expression (drug alone) in the fosphenytoin group (30 mg / kg, 6 mice), morphine group (3 mg / kg, 6 mice), or vehicle group (6 mice) in the incision model will be evaluated by immunohistochemistry (6 mice / group x 3 groups) and Western blotting (6 mice / group x 3 groups).

[0078] Experiment Schedule (1) Analgesic effect against acute pain Twenty-four hours after the model was created, fosphenytoin or morphine was administered intraperitoneally. Behavioral analysis was performed before surgery, 24 hours after surgery (before drug administration, 24 h), 1 hour after drug administration (25 h), 4 hours after drug administration (28 h), and 24 hours after drug administration (48 h). The animals were allowed to fully acclimate in the chamber before the behavioral analysis, and then the behavioral analysis was performed. [ka] (2) Morphine analgesic enhancement effect on acute pain Twenty-four hours after the model preparation, fosphenytoin and morphine were administered intraperitoneally. As in (1), behavioral analysis was evaluated before surgery, 24 hours after surgery (before drug administration, 24 h), 1 hour after drug administration (25 h), 4 hours after drug administration (28 h), and 24 hours after drug administration (48 h). (3) Inhibitory effect of pERK1 / 2 expression during acute pain Fosphenytoin or morphine was administered intraperitoneally 1 hour before model preparation. Ten minutes after surgery, the fifth lumbar dorsal root ganglion was harvested from the operated side and the expression of pERK1 / 2 was evaluated.

[0079] Drugs and reagents used The following drugs and reagents were used: Fosphenytoin Sodium: Fosphenytoin sodium 750 mg / 10 mL (Nobelpharma Co., Ltd., lot number: NP062231) Morphine hydrochloride injection: Contains 10 mg / mL of morphine hydrochloride hydrate (Daiichi Sankyo Co., Ltd., lot number: ETA0135) Isoflurane inhalation anesthetic solution "Pfizer": Isoflurane 1mL / mL (Mylan EPD LLC, lot number: 229KAR)

[0080] Immunohistochemistry ·Primary antibody ·Secondary antibody Immunohistochemistry-related reagents Immunohistochemistry-related equipment and consumables Microscope-related equipment and consumables

[0081] Western blotting ·Primary antibody ·Secondary antibody Western blotting related reagents Western blotting related equipment and consumables

[0082] Experimental animals Sprague-Dawley rats (12 weeks old, male, 200-250g, housed in groups of 3 per cage under a 12-h light-dark cycle) were used in the experiment.

[0083] Postoperative pain model Under general anesthesia with isoflurane, all rats underwent a 1-cm longitudinal incision in the skin, fascia, and plantar muscle of the left hind limb, and the skin was closed with 5-0 nylon suture to create a postoperative pain model.

[0084] Evaluation measurement (1) Behavioral analysis Von Frey stimulation (Muromachi Kikai) was used as the mechanical stimulus, and the radiant heat test (Ugo Basile) was used as the thermal stimulus, and the response to each was evaluated by behavioral analysis. (2) Immunohistochemistry After perfusion, fixation, and sucrose replacement, the tissues were frozen and sectioned using a cryostat. The sections were blocked and incubated with primary and secondary antibodies. Sections were visualized using a fluorescent microscope equipped with a digital camera (Figure 7), and images were analyzed using Image-J. The number of pERK1 / 2- and DAPI-positive neurons was counted, and the percentages were calculated. (3) Western blotting The collected DRG was homogenized in a buffer containing protease / phosphatase inhibitors, and the protein concentration of each sample was measured and homogenized. After separation by SDS-PAGE, the protein was transferred to a PVDF membrane, and the membrane was blocked and incubated with primary and secondary antibodies. Visualization was performed using the Western Blotting Detection Kit, and band signals were measured and analyzed using Image-J.

[0085] Drug administration The method of systemic administration was intraperitoneal administration. The dose was determined based on references 1 and 3. All doses were diluted with physiological saline to a total dose of 1 mL.

[0086] 4. Data Analysis Statistical analysis was performed using GraphPad Prism software or similar, using appropriate methods according to the format of the data. p<0.05 was considered statistically significant.

[0087] result (1) Analgesic effect against acute pain <mechanical sensitivity> The analgesic effects at 1 hour (25h) and 4 hours (28h) after administration of morphine 3mg / kg (M3) were significantly higher than those in the vehicle group (both p<0.01). The analgesic effect at 1 hour (25h) and 4 hours (28h) after administration of 1 mg / kg morphine (M1) was significantly (p<0.01, p<0.05) higher than that of the vehicle group. The analgesic effect at 1 hour (25h) after administration of morphine 0.3mg / kg (M0.3) was significantly (p<0.05) higher than that of the vehicle group. The analgesic effects of fosphenytoin 30 mg / kg (F30) at 1 hour (25 h) and 4 hours (28 h) were significantly higher than those of the vehicle group (both p<0.01). The analgesic effect at 1 hour (25h) and 4 hours (28h) after administration of 10mg / kg fosphenytoin (F10) was significantly (p<0.05, p<0.01) higher than that of the vehicle group. The analgesic effect of fosphenytoin 3 mg / kg (F3) was not significantly different from that of the vehicle group at any time point.

[0088] The results of the analgesic effect on acute pain (mechanical stimulation) are shown in FIG.

[0089] <thermal sensitivity> The analgesic effects at 1 hour (25h) and 4 hours (28h) after administration of morphine 3mg / kg (M3) were significantly higher than those in the vehicle group (both p<0.01). The analgesic effect at 1 hour (25h) after administration of 1mg / kg morphine (M1) was significantly (p<0.01) higher than that of the vehicle group. The analgesic effect of morphine 0.3 mg / kg (M0.3) was not significantly different from that of the vehicle group at any time point. The analgesic effect at 1 hour (25h) after administration of 30mg / kg fosphenytoin (F30) was significantly (p<0.01) higher than that of the vehicle group. The analgesic effects of fosphenytoin 10 mg / kg (F10) and fosphenytoin 3 mg / kg (F3) were not significantly different from the vehicle group at any time point.

[0090] The results of the analgesic effect on acute pain (thermal stimulation) are shown in FIG.

[0091] (2) Morphine analgesic enhancement effect on acute pain <mechanical sensitivity> The analgesic effects 1 hour (25h) and 4 hours (28h) after administration of fosphenytoin 10mg / kg + morphine 0.3mg / kg (F10+M0.3) and fosphenytoin 10mg / kg + morphine 1mg / kg (F10+M1) were significantly lower (p<0.01 for both) than morphine 3mg / kg (M3) (Figure 3). The analgesic effects of fosphenytoin 10 mg / kg + morphine 1 mg / kg (F10+M1) at 1 hour (25 h) and 4 hours (28 h) were significantly higher (both p<0.05) than those of morphine 1 mg / kg (M1), demonstrating an enhanced analgesic effect (Figure 4-A). The analgesic effect 4 hours (28 h) after administration of fosphenytoin 10 mg / kg + morphine 0.3 mg / kg (F10+M0.3) was significantly (p<0.01) higher than that of morphine 0.3 mg / kg (M0.3), demonstrating an enhanced analgesic effect (Figure 4-B).

[0092] <thermal sensitivity> The analgesic effects of fosphenytoin 10 mg / kg + morphine 0.3 mg / kg (F10+M0.3) at 1 hour (25h) and 4 hours (28h) were significantly (p<0.01, p<0.05) lower than those of morphine 3 mg / kg (M3) (Figure 5). The analgesic effect 4 hours (28 h) after administration of fosphenytoin 10 mg / kg + morphine 1 mg / kg (F10+M1) was significantly (p<0.05) higher than that of morphine 1 mg / kg (M1), demonstrating an enhanced analgesic effect (Figure 6-A). The analgesic effect 4 hours (28 h) after administration of fosphenytoin 10 mg / kg + morphine 0.3 mg / kg (F10+M0.3) was significantly (p<0.05) higher than that of morphine 0.3 mg / kg (M0.3), demonstrating an enhanced analgesic effect (Figure 6-B).

[0093] (3) Inhibitory effect of pERK1 / 2 expression during acute pain <Immunohistochemistry> Compared to the vehicle group, fosphenytoin 30 mg / kg (F30) significantly (p<0.01) decreased the percentage of total positive neurons (Figure 8). The percentage of total positive neurons in the morphine 3 mg / kg (M3) group was similar to that in the vehicle group (Figure 8). Compared to the vehicle group, fosphenytoin 30 mg / kg (F30) significantly (p<0.01) decreased the pERK+ / 3PGDH+ ratio (Figure 9). The pERK+ / 3PGDH+ ratio in the morphine 3 mg / kg (M3) group was similar to that in the vehicle group (Figure 9).

[0094] <Western blotting> The band image obtained using the Western Blotting Detection Kit is shown (Figure 10, left). Compared to the vehicle group, fosphenytoin 30 mg / kg (F30) significantly (p<0.05) decreased the pERK / GAPDH ratio (Figure 10, right). The pERK / GAPDH ratio in the pERK+ / 3PGDH+ group treated with morphine at 3 mg / kg (M3) was similar to that in the vehicle group (Figure 10, right panel).

[0095] The above test demonstrated that intraperitoneal administration of 10 mg / kg fosphenytoin had an analgesic effect almost equivalent to that of intraperitoneal administration of 1 mg / kg morphine.

[0096] Morphine has an analgesic and sedative effect during severe pain, and the dosage for adults is a subcutaneous administration of 5-10 mg at a time. In this study, 1 mg / kg of morphine was administered intraperitoneally. Although the route of administration is different, the result is a strong analgesic effect equivalent to a single administration of 50 mg of morphine in an adult human (body weight 50 kg) when converted to body weight.

[0097] Furthermore, the combined use of fosphenytoin at 10 mg / kg and morphine at 1 mg / kg and 0.3 mg / kg showed enhanced analgesic effects compared with the single administration of morphine at 1 mg / kg and 0.3 mg / kg.

[0098] Plantar incision stimulates the primary sensory nerves, which in turn activates the nerves, exacerbating acute pain and causing chronic postoperative pain. The inhibitory effect of fosphenytoin on nerve sensitization was compared with that of morphine, using phosphorylated ERK (pERK) as an index of primary sensory nerve activation. pERK expression was significantly increased in both neurons and glia in the primary sensory nerves of the postoperative pain model. pERK expression was significantly inhibited by administration of 30 mg / kg fosphenytoin, but not by 3 mg / kg morphine. These results indicate that morphine does not inhibit nerve sensitization, whereas fosphenytoin effectively inhibits it, and that fosphenytoin suppresses pain through an excellent mechanism of action.

[0099] These results not only demonstrate that fosphenytoin alone may have an excellent analgesic effect for patients with postoperative pain, but also that combining it with opioids may help reduce the amount of opioids needed.

[0100] In this study, fosphenytoin and morphine were administered intraperitoneally. In general, the increase in blood concentration is slower with intraperitoneal administration than with intravenous administration, and the maximum blood concentration is expected to be lower. Therefore, intravenous administration may have a stronger effect even if the same dose is used.

[0101] The original numerical data used to create the graphs in Figures 1 to 6 and 8 to 10 are shown below. In Tables 1 to 11, "H" stands for "time" and "Av." stands for "average value." [Table 1]

[0102] [Table 2]

[0103] [Table 3]

[0104] [Table 4]

[0105] [Table 5]

[0106] [Table 6]

[0107] [Table 7]

[0108] [Table 8]

[0109] [Table 9]

[0110] [Table 10]

[0111] [Table 11]

[0112] References 1)Takasaki I, et al. Fosphenytoin alleviates herpes simplex virus infection-induced provoked and spontaneous pain-like behaviors in mice. Biol Pharm Bull. 2022;45(3):360-363. 2) Yamakita S, et al. Synergistic activation of ERK1 / 2 between A-fiber neurons and glial cells in the DRG contributes to pain hypersensitivity after tissue injury. Mol Pain. 2018;14:174480691876750. 3)Sanna MD, et al. Regionally selective activation of ERK and JNK in morphine paradoxical hyperalgesia: a step toward improving opioid pain therapy. Neuropharmacology. 2014;86:67-77. [Industrial Applicability]

[0113] The therapeutic agent of the present invention can be used as a therapeutic agent for acute pain, particularly acute postoperative pain, and can be applied to a wide range of patients. [Brief description of the drawings]

[0114] [Figure 1] It exhibits analgesic effects against acute pain caused by mechanical stimulation. [Diagram 2] It exhibits analgesic effects against acute pain caused by thermal stimulation. [Diagram 3] This shows the potentiating effect of morphine on acute pain induced by mechanical stimulation. [Figure 4] The morphine analgesic enhancing effect on acute pain induced by mechanical stimulation is shown. (A) is 1 mg / kg morphine, and (B) is 0.3 mg / kg morphine. [Diagram 5] This shows the potentiating effect of morphine on acute pain induced by thermal stimulation. [Figure 6] The morphine analgesic enhancing effect on acute pain induced by thermal stimulation is shown. (A) is 1 mg / kg morphine, and (B) is 0.3 mg / kg morphine. [Figure 7] The image was taken using a fluorescent microscope equipped with a digital camera. [Figure 8] The percentage of total positive neurons is shown. [Figure 9] The pERK positive / 3PGDH positive ratio is shown. [Figure 10] The band image (left) and the pERK / GAPDH ratio (right) obtained by the Western Blotting Detection Kit are shown.

Claims

1. A therapeutic agent for acute pain comprising, as an active ingredient, a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin)valeric acid and ethotoin.

2. 2. The therapeutic agent according to claim 1, wherein the active ingredient is phenytoin or fosphenytoin.

3. The therapeutic agent according to claim 1, wherein the active ingredient is fosphenytoin.

4. The therapeutic agent according to claim 1, wherein the acute pain is postoperative pain.

5. The therapeutic agent of claim 1 , which is administered in combination with an opioid.

6. The method of claim 5, wherein the opioid is morphine.

7. A pharmaceutical composition for treating acute pain comprising a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin)valeric acid and ethotoin, and a pharma- ceutically acceptable carrier.

8. The pharmaceutical composition according to claim 7, which is an injection, an oral preparation or a transdermal preparation.

9. The pharmaceutical composition according to claim 7, which is an injection.

10. 8. The pharmaceutical composition of claim 7, wherein the active ingredient is phenytoin or fosphenytoin.

11. 8. The pharmaceutical composition of claim 7, wherein the active ingredient is fosphenytoin.

12. The pharmaceutical composition according to claim 7, wherein the acute pain is post-operative pain.

13. The pharmaceutical composition of claim 7 , in combination with administration of an opioid.

14. 14. The pharmaceutical composition of claim 13, wherein the opioid is morphine.

15. The pharmaceutical composition of claim 7 , which is administered simultaneously with administration of an opioid.

16. 16. The pharmaceutical composition of claim 15, wherein the opioid is morphine.

17. 17. The pharmaceutical composition of claim 14 or claim 16, wherein the hydantoin compound is fosphenytoin and the opioid is morphine.

18. The pharmaceutical composition according to claim 14 or 16, wherein the weight ratio of the hydantoin compound to morphine is within the range of 1000:1 to 1:1000.

19. 19. The pharmaceutical composition of claim 18, wherein the weight ratio of fosphenytoin to morphine is within the range of 100:1 to 100:20.

Citation Information

Patent Citations

  • Therapeutic agent for acute herpes zoster pain

    WO2020054872A1